Cargando…
Elevated levels of thymidine kinase 1 peptide in serum from patients with breast cancer
OBJECTIVES: Thymidine kinase (TK) has an important role in DNA synthesis and is thus related to cell proliferation and turn-over. Traditionally, TK has been measured by enzymatic activity or radioimmunoassays. These assays are difficult to adapt to random access instruments. The aim of this study wa...
Autores principales: | , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Informa Healthcare
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2852757/ https://www.ncbi.nlm.nih.gov/pubmed/19396699 http://dx.doi.org/10.1080/03009730802688835 |
_version_ | 1782179978373234688 |
---|---|
author | Carlsson, Lena Larsson, Anders Lindman, Henrik |
author_facet | Carlsson, Lena Larsson, Anders Lindman, Henrik |
author_sort | Carlsson, Lena |
collection | PubMed |
description | OBJECTIVES: Thymidine kinase (TK) has an important role in DNA synthesis and is thus related to cell proliferation and turn-over. Traditionally, TK has been measured by enzymatic activity or radioimmunoassays. These assays are difficult to adapt to random access instruments. The aim of this study was to evaluate a new immunological sandwich assay for detection of TK peptides in serum from breast cancer patients. MATERIAL AND METHODS: Serum samples were collected from patients with breast cancer and stored frozen at −70°C. The samples were collected after surgery, after metastatic tumor recurrence and after chemotherapy due to tumour recurrence. Patients’ serum samples were analysed by the TK enzyme-linked immunosorbent assay (ELISA). RESULTS: In receiver operating characteristics (ROC) analyses of TK1 for diagnosis of breast cancer, the area under the curve (AUC) collected four weeks after surgery was 0.56 (95% CI 0.47–0.65), for samples collected postsurgically after tumour recurrence 0.73 (95% CI 0.65–0.80), and after chemotherapy 0.64 (95% CI 0.56–0.72). CONCLUSIONS: This study indicates that the tumour proliferation marker TK has a potential as a serum marker in breast cancer. Further studies are warranted to verify this observation. |
format | Text |
id | pubmed-2852757 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Informa Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-28527572010-05-19 Elevated levels of thymidine kinase 1 peptide in serum from patients with breast cancer Carlsson, Lena Larsson, Anders Lindman, Henrik Ups J Med Sci Original Article OBJECTIVES: Thymidine kinase (TK) has an important role in DNA synthesis and is thus related to cell proliferation and turn-over. Traditionally, TK has been measured by enzymatic activity or radioimmunoassays. These assays are difficult to adapt to random access instruments. The aim of this study was to evaluate a new immunological sandwich assay for detection of TK peptides in serum from breast cancer patients. MATERIAL AND METHODS: Serum samples were collected from patients with breast cancer and stored frozen at −70°C. The samples were collected after surgery, after metastatic tumor recurrence and after chemotherapy due to tumour recurrence. Patients’ serum samples were analysed by the TK enzyme-linked immunosorbent assay (ELISA). RESULTS: In receiver operating characteristics (ROC) analyses of TK1 for diagnosis of breast cancer, the area under the curve (AUC) collected four weeks after surgery was 0.56 (95% CI 0.47–0.65), for samples collected postsurgically after tumour recurrence 0.73 (95% CI 0.65–0.80), and after chemotherapy 0.64 (95% CI 0.56–0.72). CONCLUSIONS: This study indicates that the tumour proliferation marker TK has a potential as a serum marker in breast cancer. Further studies are warranted to verify this observation. Informa Healthcare 2009-06 2009-04-24 /pmc/articles/PMC2852757/ /pubmed/19396699 http://dx.doi.org/10.1080/03009730802688835 Text en © Upsala Medical Society http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the source is credited. |
spellingShingle | Original Article Carlsson, Lena Larsson, Anders Lindman, Henrik Elevated levels of thymidine kinase 1 peptide in serum from patients with breast cancer |
title | Elevated levels of thymidine kinase 1 peptide in serum from patients with breast cancer |
title_full | Elevated levels of thymidine kinase 1 peptide in serum from patients with breast cancer |
title_fullStr | Elevated levels of thymidine kinase 1 peptide in serum from patients with breast cancer |
title_full_unstemmed | Elevated levels of thymidine kinase 1 peptide in serum from patients with breast cancer |
title_short | Elevated levels of thymidine kinase 1 peptide in serum from patients with breast cancer |
title_sort | elevated levels of thymidine kinase 1 peptide in serum from patients with breast cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2852757/ https://www.ncbi.nlm.nih.gov/pubmed/19396699 http://dx.doi.org/10.1080/03009730802688835 |
work_keys_str_mv | AT carlssonlena elevatedlevelsofthymidinekinase1peptideinserumfrompatientswithbreastcancer AT larssonanders elevatedlevelsofthymidinekinase1peptideinserumfrompatientswithbreastcancer AT lindmanhenrik elevatedlevelsofthymidinekinase1peptideinserumfrompatientswithbreastcancer |